Properties of Monocyte-Derived Dendritic Cells Loaded With Lysates of Cancer Cells Exposed to Cytotoxic Peptides

N Khranovska1, O Skachkova1, O Gorbach1

  • 1Nonprofit organization "National Cancer Institute", Kyiv, Ukrainee.

Experimental Oncology
|February 22, 2025
PubMed
Abstract

Insights

Cytotoxic peptides (CPs) induce cancer cell death, generating tumor lysates that activate dendritic cells (DCs) for a novel anticancer vaccine. This approach enhances DC maturation without inducing immunosuppressive properties, paving the way for effective immunotherapies.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Utilizing cytotoxic peptides (CPs) to induce tumor cell membrane lysis for cancer immunotherapy.
  • Leveraging cancer cells undergoing immunogenic cell death to release damage-associated molecular patterns (DAMPs).
  • Enhancing immunogenic maturation and activation of dendritic cells (DCs) for an anticancer vaccine.

Purpose of the Study:

  • To analyze the phenotypic and functional characteristics of monocyte-derived DCs.
  • To evaluate DCs loaded with tumor cell lysates treated with diarylethene-containing CPs (LMB033).
  • To assess the potential of this approach for developing a DCs-based anticancer vaccine.

Main Methods:

  • Treatment of MDA-MB-231 triple-negative breast cancer cells with LMB033 CPs in "open" and "closed" forms.
  • Generation of DCs from peripheral blood monocytes using GM-CSF and IL-4.
  • Analysis of DC phenotype (CD83, CD86, CD11c, HLA-DR, HLA-ABC) via flow cytometry.
  • Quantification of cytokine and indoleamine 2,3-dioxygenase (IDO) gene expression using real-time PCR.

Main Results:

  • LMB033's open form demonstrated significant cytotoxicity against MDA-MB-231 cells.
  • CPs induced phosphatidylserine externalization, indicating apoptosis in tumor cells.
  • Loading DCs with CPs-treated lysates increased the number of mature, activated CD83+ DCs.
  • No significant changes in Th1 polarizing cytokines or immunosuppressive genes (IL-10, TGF-β, IDO) were observed.

Conclusions:

  • CPs-LMB033-treated tumor cell lysates effectively mature and activate DCs.
  • The generated DCs do not exhibit immunosuppressive properties.
  • This strategy shows promise for developing an effective DCs-based antitumor immunotherapeutic vaccine.